The latest news on CMT treatments, trials and research.
Pharnext PXT3003 Phase III Update
June 10th, 2020
Pharnext SA , a biopharmaceutical company, today provided an update on the regulatory and clinical status of PXT3003, its lead program in Charcot-Marie-Tooth Type 1A (“CMT1A”). PXT3003 is a novel drug candidate for the treatment of CMT1A and has...
Sarepta Therapeutics and Dyno Therapeutics to Develop Next-Generation Gene Therapy
May 11th 2020
Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, and Dyno Therapeutics, Inc., a biotech company applying artificial intelligence (AI) to gene therapy, today announced an agreement to develop next-generation A...
Regenacy Pharmaceuticals Raises $30 Million
March 25th, 2020
Regenacy Pharmaceuticals, a clinical-stage biopharmaceutical company developing breakthrough treatments for diabetic and other peripheral neuropathies, today announced the closing of a $30 million Series A financing. The financing was co-led by Co...
Pharnext Announces PXT3003 for CMT-1A
March 18th, 2020
Pharnext, a biopharmaceutical company pioneering a new approach to developing innovative drug combinations based on big genomics data and artificial intelligence, today announced that the United Kingdom's Medicine and Healthcare products Regulator...